Literature DB >> 10533840

Automatic attentional shifts induced by a noradrenergic drug in Alzheimer's disease: evidence from evoked potentials.

P Missonnier1, R Ragot, C Derouesné, D Guez, B Renault.   

Abstract

Prior research showed that attentional deficits are observed in Alzheimer's disease (AD). These deficits can further impair other cognitive processes. The present experiment was designed to study the shifts in attention induced by a noradrenergic drug (S 12024-2) through their electrophysiological correlates in 12 outpatients with mild AD, using an auditory oddball paradigm. The P3a component, known to be related to automatic attentional processing, was increased by the drug, whereas no changes occurred either in PN or in P3b, which are considered to reflect conscious processing. These results point to an involvement of the noradrenergic system in the modulation of automatic attentional processing, and provide evidence for weakening of the orienting reflex in AD, due to a possible noradrenergic deficit in patients with mild AD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10533840     DOI: 10.1016/s0167-8760(99)00059-8

Source DB:  PubMed          Journal:  Int J Psychophysiol        ISSN: 0167-8760            Impact factor:   2.997


  3 in total

Review 1.  Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer's Disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurotox Res       Date:  2016-06-23       Impact factor: 3.911

2.  Dynamics of attentional selection under conflict: toward a rational Bayesian account.

Authors:  Angela J Yu; Peter Dayan; Jonathan D Cohen
Journal:  J Exp Psychol Hum Percept Perform       Date:  2009-06       Impact factor: 3.332

3.  Social Media Approval Reduces Emotional Arousal for People High in Narcissism: Electrophysiological Evidence.

Authors:  Kyle Nash; Andre Johansson; Kumar Yogeeswaran
Journal:  Front Hum Neurosci       Date:  2019-09-20       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.